CEP192: A Potential Drug Target for Cancer (G55125)

Target Name: CEP192

NCBI ID: G55125

CEP192

CEP192: A Potential Drug Target for Cancer

Centrosomal protein 192 (CEP192) is a protein that is expressed in various cell types, including neurons and cancer cells. It is a key component of the centrosome, which is a structure that forms in the center of each cell and is involved in cell division.

CEP192 is a transmembrane protein that is characterized by its ability to interact with other proteins in the cell. It is made up of four structural domains: a N-terminus, a T-terminus, a middle transmembrane region, and an C-terminus. The N-terminus of CEP192 contains a region that is involved in the interaction with microtubules, while the T-terminus contains a region that is involved in the interaction with the cytoskeleton.

One of the unique features of CEP192 is its ability to interact with the protein tau. Tau is a protein that is involved in the regulation of cell division and is often associated with the development of neurodegenerative diseases. CEP192 has been shown to interact with tau and can modulate its activity. This interaction between CEP192 and tau is thought to be involved in the regulation of cell division and the development of cancer.

Another potential mechanism by which CEP192 may be involved in the regulation of cell division is its ability to interact with the protein p16INK4a. P16INK4a is a tumor suppressor protein that is often disrupted in cancer cells. CEP192 has been shown to interact with p16INK4a and can modulate its activity. This interaction between CEP192 and p16INK4a is thought to be involved in the regulation of cell growth and the inhibition of cancer cell proliferation.

In addition to its potential role in the regulation of cell division, CEP192 may also be involved in the development of cancer. For example, studies have shown that CEP192 is overexpressed in various types of cancer, including breast cancer and lung cancer. This overexpression of CEP192 may contribute to the development and progression of cancer.

Another potential mechanism by which CEP192 may be involved in the development of cancer is its ability to interact with the protein MDM4. MDM4 is a transcription factor that is involved in the regulation of gene expression and is often disrupted in cancer cells. CEP192 has been shown to interact with MDM4 and can modulate its activity. This interaction between CEP192 and MDM4 is thought to be involved in the regulation of gene expression and the development of cancer.

In conclusion, CEP192 is a protein that is involved in various cellular processes, including the regulation of cell division and the development of cancer. Its ability to interact with other proteins, including tau, p16INK4a, and MDM4, suggests that it may be a potential drug target or biomarker for the treatment of various types of cancer. Further research is needed to fully understand the role of CEP192 in the regulation of cell division and the development of cancer.

Protein Name: Centrosomal Protein 192

Functions: Required for mitotic centrosome maturation and bipolar spindle assembly (PubMed:25042804, PubMed:17980596, PubMed:18207742). Appears to be a major regulator of pericentriolar material (PCM) recruitment, centrosome maturation, and centriole duplication (PubMed:25042804, PubMed:17980596, PubMed:18207742). Centrosome-specific activating scaffold for AURKA and PLK1 (PubMed:25042804)

The "CEP192 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP192 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets